Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of azacitidine in high-risk MDS/AML with chromosome 7 or complex cytogenetic abnormalities
2005-003732-22Phase 2Terminated
- Sponsor
- King's College London
- Start
- Sep 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by King's College London. Primary endpoints: Complete remission, Cytogenetic remission and 1 more. Started Sep 2005; status: terminated.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2005-003732-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003732-22.